Equillium is a company headquartered in the United States.
Equillium develops immunology-based therapies targeting severe autoimmune and inflammatory diseases using novel modalities such as multi-cytokine inhibitory peptides and AhR modulators in clinical trials for conditions like acute Graft-Versus-Host Disease, asthma, and lupus nephritis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.